Regenerative medicine company Aziyo Biologics sets terms for $50 million IPO

Aziyo Biologics, which makes regenerative medical products for various tissue types, announced terms for its IPO on Wednesday.

The Silver Spring, MD-based company plans to raise $50 million by offering 2.9 million shares at a price range of $16 to $18. Insiders intend to purchase $20 million worth of shares in the offering. At the midpoint of the proposed range, Aziyo Biologics would command a fully diluted market value of $177 million.

Through its proprietary tissue processing platforms, the company has developed a portfolio of advanced regenerative medical products designed to be similar to natural biological material. Its core products are designed to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. 

Aziyo Biologics was founded in 2015 and booked $42 million in revenue for the 12 months ended June 30, 2020. It plans to list on the Nasdaq under the symbol AZYO. Piper Sandler, Cowen,

Read More

Compass Pathways (NASDAQ:CMPS) IPO Proves Psychedelic Medicine Investment Thesis

WPSS Investments, a pioneer biotech Venture Capital fund focused on brain health and psychedelic medicine, celebrates the successful IPO of its portfolio company Compass Pathways. 

On September 18th, 2020 Compass Pathways was listed on NASDAQ (NASDAQ:CMPS), making it the first psychedelic company to be listed on a U.S. exchange. CMPS´s price per share has surged more than 100% since its initial listing price of 17USD, turning it into the most valuable and first unicorn psychedelic medicine company in the world.

Compass Pathways, was co-founded several years ago by George Goldsmith and Ekaterina Malievskaia who experienced the painful effects of depression within their own family.  Together Lars Christian Wilde they set out to develop psilocybin (the active compound in magic mushrooms) for use in patients with treatment-resistant depression. Compass Pathways is currently in phase II trials of the FDA which should bring in promising results in 2021.

WPSS invested in Compass

Read More

CNS biotech Praxis Precision Medicine files for a $100 million IPO

Praxis Precision Medicines, a Phase 2 biotech developing therapies for CNS disorders using genetic insights, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

The company’s pipeline contains its most advanced candidates, PRAX-114 and PRAX-944, which are in Phase 2 development for major depressive disorder/perimenopausal depression and essential tremor, respectively. The company plans to initiate a Phase 2/3 trial for PRAX-114 in the US and Australia in the 4Q20, with topline data expected in the 2H21.

The Cambridge, MA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol PRAX. Praxis Precision Medicines filed confidentially on July 22, 2020. Cowen, Evercore ISI and Piper Sandler are the joint bookrunners on the deal. No pricing terms were disclosed.

The article CNS biotech Praxis Precision Medicine files for a $100 million IPO originally appeared on IPO investment manager

Read More